AME-527

AME-527 is a humanized monoclonal antibody designed to target and neutralize tumor necrosis factor-alpha (TNF-alpha). It was originally developed by Applied Molecular Evolution (AME) using their proprietary directed evolution technology, which allowed for the selection of antibody variants with significantly improved binding affinity and potency compared to existing anti-TNF agents. Following the acquisition of AME by Eli Lilly and Company in 2004, AME-527 was advanced into Phase 1 clinical trials for the treatment of rheumatoid arthritis and was also explored for other inflammatory conditions such as Crohn's disease. The therapeutic goal was to inhibit the pro-inflammatory signaling cascade mediated by TNF-alpha, a key cytokine in the pathogenesis of several autoimmune disorders. However, Eli Lilly discontinued the development of AME-527 in the mid-2000s, and the program did not advance to late-stage clinical testing.

Other names

humanized anti-TNF-alpha monoclonal antibodyanti-TNF-alpha antibody